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The present study developed physiologically-based kinetic (PBK) models for the alkenylbenzene apiol in
order to facilitate risk assessment based on read-across from the related alkenylbenzene safrole. Model
predictions indicate that in rat liver the formation of the 10-sulfoxy metabolite is about 3 times lower for
apiol than for safrole. These data support that the lower conﬁdence limit of the benchmark dose resulting
in a 10% extra cancer incidence (BMDL10) that would be obtained in a rodent carcinogenicity study with
apiol may be 3-fold higher for apiol than for safrole. These results enable a preliminary risk assessment
for apiol, for which tumor data are not available, using a BMDL10 value of 3 times the BMDL10 for safrole.
Based on an estimated BMDL10 for apiol of 5.7e15.3 mg/kg body wt per day and an estimated daily intake
of 4  105 mg/kg body wt per day, the margin of exposure (MOE) would amount to 140,000e385,000.
This indicates a low priority for risk management. The present study shows how PBK modelling can
contribute to the development of alternatives for animal testing, facilitating read-across from compounds
for which in vivo toxicity studies on tumor formation are available to compounds for which these data
are unavailable.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Apiol (1-allyl-2,5-dimethoxy-3,4-methylenedioxybenzene) is
one of alkenylbenzene compounds found in herbs and other bo-
tanicals like parsley, fennel, nutmeg and elemi tree. High levels ofe-1,2-diol; BMDL10, the lower
10% extra cancer; DHA, 20 ,30-
opean Food Safety Authority;
roxyapiol glucuronide; HAO,
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iquid chromatography.
eningen University, Tuinlaan
799988728.
ouni).
Ltd. This is an open access article uapiol are especially present in parsley and apiol gives parsley its
characteristics odour (Miller et al., 1983; Parthasarathy et al., 2008;
Tunali et al., 1999). Parsley parts (leaves, stems, roots and seeds) are
used as food ﬂavouring agent in many food types such as sauces,
soups, stufﬁng, rissoles, and minces, and are also sprinkled over
vegetables or salads. Beside the use of parsley in food, medicinal
uses of apiol extracted from the Triple Moss curled variety of
parsley have been reported (Parthasarathy et al., 2008). The
structure of apiol is closely related to that of safrole, myristicin,
estragole, methyleugenol, and elemicin (Fig. 1).
These alkenylbenzenes are of concern because they can be
converted to DNA reactive 10-sulfoxy metabolites that readily form
DNA adducts that may contribute to the formation of hepatomas in
rodent bioassays upon exposure to these alkenylbenzenes at high
dose levels (Miller et al., 1983; Randerath et al., 1984; SCF, 2001a,
2001b, 2002; Wiseman et al., 1987). DNA adduct formationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The structural formulas of the alkenylbenzenes estragole, methyleugenol, ele-
micin, safrole, myristicin and apiol.
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ways presented in Fig. 2 (WHO, 2009). Apiol however is less well
studied than its related alkenylbenzene safrole and rodent carci-
nogenicity studies on apiol are not available hampering its risk
assessment.
The structural similarity of apiol to safrole raises a concern and
provides a rationale for an updated risk assessment of exposure to
apiol via food including food supplements. Several studies have
reported on the DNA adduct formation by apiol in animal in vivo
studies or in human in vitro models as compared to the related
alkenylbenzenes and found apiol to be less potent than its struc-
tural analogues (Miller et al., 1983; Randerath et al., 1984; Phillips
et al., 1984; Zhou et al., 2007).
The safety of human exposure to apiol has been assessed by the
WHO in 2009 concluding that the structural similarities to safroleFig. 2. Suggested metabolwith available experimental data give evidence that apiol may
cause toxicity and carcinogenicity in rodents exposed to high dose
levels (WHO, 2009). Because rodent bioassays characterizing the
possible carcinogenicity of apiol are not available, the aim of the
present study was to perform a risk assessment for apiol based on
PBK-modelling based read-across from safrole for which rodent
tumor data are available (Miller et al., 1983; Randerath et al., 1984;
Phillips et al., 1984).2. Materials and methods
Caution: Apiol and 10-hydroxyapiol are possible carcinogens
and should be handled with care.2.1. Chemicals and reagents
Apiol, uridine 50-diphosphoglucuronic acid trisodium salt
(UDPGA), reduced L-glutathione (GSH), alamethicin (from Tricho-
derma viride), and 30-phosphoadenosine-50-phosphosulfate (PAPS)
were obtained from Sigma Aldrich (Zwijndrecht, Netherlands).
Reduced b-nicotinamide adenine dinucleotide phosphate (NADPH)
and nicotinamide adenine dinucleotide (NADþ) were from Roche
Diagnostic (Mannheim, Germany), and dimethyl sulfoxide (DMSO)
was obtained from Acros Organics (Geel, Belgium). Chromato-
graphic grade triﬂuoroacetic acid (TFA) was obtained from Merck
(Darmstadt, Germany). Potassium dihydrogen phosphate, dipotas-
sium hydrogen phosphate trihydrate, acetic acid, and magnesium
chloride were provided by VWR International (Darmstadt, Ger-
many). Acetonitrile (ACN) (ULC/MS grade) was purchased from
Biosolve BV (Valkenswaard, The Netherlands).
Pooled male rat liver microsomes and S9 from SpragueeDawley
and mixed gender pooled human liver microsomes and S9 wereic pathways of apiol.
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gueeDawley rat lung, kidney, and small intestinal microsomes and
pooled gender human lung, kidney, and intestinal microsomes
were purchased from BioPredic International (Rennes, France).
2.2. Synthesis of 10-hydroxyapiol and 10-oxoapiol
The synthesis of 10-hydroxyapiol from apiol was done as
described previously for the synthesis of 10-hydroxysafrole from
safrole by Jeurissen et al. (2004) and 10-oxoapiol was synthesized
from 10-hydroxyapiol according to the method used for synthesis of
10-oxoestragole from 10-hydroxyestragole (Wislocki et al., 1976).
2.3. In vitro incubations
2.3.1. Microsomal metabolism of apiol by rat and human
microsomes
Liver, kidney, lung and small intestine microsomes from male
Sprague Dawley rat and from human were used to determine
tissue-speciﬁcity of the microsomal biotransformation of apiol in
rat and human. Incubations were performed by adding 1 mg/ml of
the microsomal protein preparation to an incubation mixture
containing (ﬁnal concentrations) 3 mM NADPH in 0.2 M TriseHCl
(pH 7.4). After a 1 min pre-incubation at 37 C, apiol (ﬁnal con-
centration 1000 mM) was added from a 100 times concentrated
stock solution in DMSO so that the ﬁnal DMSO contentwas 1% (v/v).
After 120 min incubation at 37 C for rat and human microsomes
the reactions were terminated by adding 25 ml ice-cold acetonitrile.
All samples were centrifuged for 5 min at 16,000 g and the su-
pernatant was stored at 20 C until Ultra Performance Liquid
Chromatography (UPLC) analysis.
For both male rat and human, metabolism of apiol was only
observed in incubations with liver microsomes (See the Results
section) and hence kinetic constants for the formation of micro-
somal metabolites were determined only for liver microsomes. To
determine the kinetic constants incubations following the condi-
tions described above were done using ﬁnal concentrations of apiol
from 25 to 1000 mM for rat and human liver while keeping the
DMSO content at 1% (v/v). Blank incubations were performed in the
absence of the cofactor NADPH. All incubations were performed in
triplicate.
2.3.2. Glucuronidation of 10-hydroxyapiol to 10-hydroxyapiol
glucuronide by rat and human liver S9
The kinetic constants for the metabolic conversion of 10-
hydroxyapiol to 10-hydroxyapiol glucuronide in incubations with
both male rat and human liver fractions were determined as
described previously for related 10-hydroxyalkenylbenzenes (Al-
Subeihi et al., 2012, 2011; Martati et al., 2011a, 2012a; Punt et al.,
2008, 2009; van den Berg et al., 2012). In short, incubations were
performed using (ﬁnal concentrations) 10 mM UDPGA and 0.5 mg/
mL male SpragueeDawley rat or pooled gender human S9 protein
in 0.2 M TriseHCl (pH 7.4) containing 10 mM MgCl2. First the in-
cubations were pre-treated on ice for 15 min with 0.025 mg/mL
alamethicin added from a 200 times concentrated stock solution in
methanol to overcome enzyme latency and to obtain maximal
glucuronidation activity. After the pre-treatment on ice and pre-
incubation at 37 C for 1 min, the reactions were subsequently
started by adding 10-hydroxyapiol in ﬁnal concentrations of
10e2000 mM. 10-Hydroxyapiol was added from 100 times concen-
trated stock solutions dissolved in DMSO. The reaction was incu-
bated for 30 and 120 min for rat and human S9, respectively, and
terminated by adding 25 mL of ice-cold acetonitrile. Blank in-
cubations were carried out in the absence of the cofactor UDPGA.
Experiments were performed in triplicate. All samples werecentrifuged for 5 min at 16000 g, and the supernatant was stored
at 20 C until UPLC analysis.
2.3.3. Oxidation of 10-hydroxyapiol to 10-oxoapiol by rat and
human liver microsomes
The kinetic constants for the enzymatic conversion of 10-
hydroxyapiol to 10-oxoapiol were determined using incubation
mixtures containing (ﬁnal concentrations) 3 mMNADþ, 2 mMGSH,
and 1 mg/mL rat or human liver microsomes in 0.2 M TriseHCl (pH
7.4). GSH was added to the incubation mixtures to trap the reactive
10-oxometabolite formed after oxidation of 10-hydroxyapiol. To
determine the kinetic constants incubations following the condi-
tions described above were done using ﬁnal concentrations of 10-
hydroxyapiol from 50 to 2000 mM added to the incubation mixture
from 100 times concentrated stock solutions in DMSO. After pre-
incubation for 1 min at 37 C the reactions were started by add-
ing the 10-hydroxyapiol and were terminated after 60 min of in-
cubation at 37 C by adding 25 mL of ice-cold acetonitrile. The
formation of the GSH conjugate of 10-oxoapiol, GS-10-oxoapiol, was
linear with time and microsomal protein under the experimental
conditions used. Blank incubations were performed without the
cofactor NADþ. Incubations were performed in triplicate. All sam-
ples were centrifuged for 5 min at 16000 g, and the supernatant
was stored at 20 C until UPLC analysis.
2.3.4. Sulfonation of 10-hydroxyapiol to 10-sulfoxyapiol by rat and
human liver S9
The kinetic constants for the enzymatic conversion of 10-
hydroxyapiol to 10-sulfoxyapiol were determined using incubation
mixtures containing (ﬁnal concentrations) 10 mM GSH, 0.2 mM
PAPS, and 3 mg/mL SpragueeDawley rat or mixed gender pooled
human liver S9 proteins in 0.1 M potassium phosphate buffer (pH
8.0). GSH was used as a scavenger of the reactive carbocation
formed due to the unstable nature of the 10-sulfoxymetabolite in an
aqueous environment. After pre-incubation for 1 min at 37 C 10-
hydroxyapiol dissolved in DMSO was added in ﬁnal concentrations
ranging between 50 and 2000 mM, while keeping the ﬁnal DMSO
content at 1% (v/v). The reaction was terminated after 360 min by
adding 25 mL of ice-cold acetonitrile. The formation of the GSH
conjugate of 10-sulfoxyapiol was linear with time and S9 protein
concentration under the experimental conditions used. The scav-
enging may either be chemically or catalysed by the glutathione S-
transferases present in the S9 incubations in which the sulfonation
of 10-hydroxyapiol was measured. Blank incubations were per-
formed in the absence of PAPS. Incubations were performed in
triplicate. All samples were centrifuged for 5 min at 16000 g, and
the supernatant was stored at 20 C until UPLC analysis.
2.4. Identiﬁcation and quantiﬁcation of apiol metabolites
Apiol metabolites formed in microsomal incubations were
identiﬁed using a photodiode array detection (UPLC-PDA)
composed of a Waters (Waters, Milford, MA) Acquity solvent
manager, sample manager, and diode array detector, equipped with
a Water Acquity UPLC BEH C18 column. The gradient was made
with a mixture of ACN and ultrapure water containing 0.1% (v/v)
TFA. The ﬂow ratewas 0.6ml/min. After equilibrating the column at
starting condition of 10% ACN, ACN increased to 50% over 4 min,
was further increased to 80% over 0.5 min, decreased to 10% over
0.5 min and was ﬁnally kept at 10% for 1 min. Metabolites were
identiﬁed as described in the Result section. Quantiﬁcation of
microsomal apiol metabolites was done by comparison of the peak
areas obtained at awavelength of 208 nm to the calibration curve of
synthesized 10-hydroxyapiol because UV spectra of all metabolites
were similar.
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mined using the same UPLC-PDA system as described above. The
gradient was made with acetonitrile and ultrapure water contain-
ing 0.1% (v/v)TFA. The ﬂow ratewas 0.6 ml/min. In a mixture of ACN
and ultrapure water containing 0.1% (v/v) TFA, the gradient started
at 10% ACN, increased to 60% ACN over 3.5 min, further increased to
80% over 0.5 min, kept at 80% ACN for 0.5 min and then decreased
to 10% ACN over 0.5 min. 10-hydroxyapiol glucuronide was identi-
ﬁed as described in the Result section. Quantiﬁcation of 10-
hydroxyapiol glucuronide was done by comparison of the peak
areas obtained at awavelength of 208 nm to the calibration curve of
synthesized 10-hydroxyapiol.
The concentration of the glutathione conjugate of 10-oxoapiol
was determined using the same UPLC-PDA system as described
above. The gradient was made with acetonitrile and ultrapure
water containing 0.1% (v/v)TFA. The ﬂow rate was 0.6 ml/min. In a
mixture of ACN and ultrapure water containing 0.1% (v/v) TFA, the
gradient started at 10% ACN, increased to 30% ACN over 2.5 min,
was further increased to 80% ACN over 0.5 min, kept at 80% ACN for
0.5 min and ﬁnally decreased to 10% ACN over 0.5 min, and kept at
10% ACN for 0.5 min. Quantiﬁcation of the GSH adduct of the
metabolite was done by comparison of the peak areas obtained at a
wavelength of 280 nm to the calibration curve of the GSH adduct of
the synthesized 10-oxoapiol.
The concentration of the glutathione conjugate of 10-sulfox-
yapiol was determined using the same UPLC-PDA system described
above. The ﬂow rate was 0.6 ml/min. In a mixture of ACN and ul-
trapure water containing 0.1% (v/v) TFA, the gradient started at 0%
ACN, increased to 20% ACN over 0.2 min, further increased to 30%
ACN over 4.3 min, and again increased to 100% ACN over 0.3 min,
kept at 100% ACN for 0.2 min, and ﬁnally decreased to 0% ACN over
0.2 min and kept at 0% ACN for 0.8 min. The GSH adduct of 10-
sulfoxyapiol formed was identiﬁed by LC-MS using a microOTOF
MS (Bruker) coupled to an Agilent LC (1200 Series) equipped with
an Alltima C18 column (150  4.6 mm, 3 mm). The mobile phase
used consisted of nanopure water with 0.1% formic acid and ACN
with 0.1% formic acid. Elution was at a ﬂow rate of 0.8 ml/min,
starting at 22% ACN with a linear increase to 100% ACN in 30 min.
Subsequently, the gradient returned linearly to the initial condition
in 2 min and remained 13 min at this condition prior to the next
injection. Quantiﬁcation of the GSH adduct of 10-sulfoxyapiol was
done by comparison of the peak areas obtained at a wavelength of
280 nm to the calibration curve of the GSH adduct of synthesized
10-oxoapiol since their UV spectra are comparable. Mass spectro-
metric analysis was in the negative electrospraymode using a spray
capillary voltage of 4500 V, a capillary temperature of 200 C and
nitrogen as nebulizer gas at 8.0 L/min.
2.5. Determination of kinetic constants of apiol and 10-hydroxyapiol
metabolic conversions
Kinetic constants for the metabolic conversions of apiol and 10-
hydroxyapiol were calculated by two equations depending on the
dose-dependency of the kinetics of the conversion. If the reaction
reached saturation with increasing substrate concentration, the
kinetic constants were derived by ﬁtting the data to the standard
MichaeliseMenten equation; v¼ Vmax [S]/(Kmþ [S]), inwhich [S]
represents the substrate concentration, Vmax themaximumvelocity
and Km the MichaeliseMenten constant for the formation of the
different metabolites of apiol or 10-hydroxyapiol. Data analysis was
accomplished using GraphPad Prism, version 5.04 (GraphPad
Software, San Diego, California, USA). When the reaction did not
reach saturation and rather displayed a linear increase in the rate of
conversionwith increasing substrate concentration, the kinetic rate
constant for a ﬁrst order reaction was derived by using thefollowing equation; v ¼ k$[S], with k being the ﬁrst order rate
constant and [S] representing the substrate concentration.2.6. Apiol PBK models in rat and human
PBK models were developed describing the dose-dependent
bioactivation and detoxiﬁcation of apiol in respectively rat and
human. The apiol models were based on the PBKmodels previously
deﬁned for the metabolism of estragole, methyleugenol, elemicin
and safrole in rat (Al-Subeihi et al., 2011; Martati et al., 2011a; Punt
et al., 2008; van den Berg et al., 2012) and human (Al-Subeihi et al.,
2012; Martati et al., 2012a; Punt et al., 2009; van den Berg et al.,
2012). Fig. 3 presents an overview of the developed PBK models
for apiol metabolism in rat and human.
The models consist of several compartments representing
different organs and tissues (i.e. liver, fat tissue, rapidly perfused
tissues and slowly perfused tissues) which are connected through
the systemic circulation. First order kinetics was used to describe
the uptake of apiol from the gastrointestinal tract assuming a direct
and complete uptake by the liver with an absorption rate constant
(ka) of 1.0 h1 which is based on the fast and complete absorption of
the structurally related alkenylbenzene estragole from the gastro-
intestinal tract (WHO, 2009).
For both rat and human, only the liver microsomes were able to
convert apiol to different microsomal metabolites (see Result sec-
tion) and this is why no other tissue compartments were described
as separate compartments in the model. In liver microsomal in-
cubations 20,30-dihydroxyapiol (DHA), 10-hydroxyapiol (HA), and 4-
allyl-3,6-dimethoxybenzene-1,2-diol (ADD) were formed and their
formation was included. Since 20,30-dihydroxyapiol is formed after
hydrolysis of apiol-20,30-oxide, data for both metabolites that result
from epoxidation of apiol were combined and referred to as 20,30-
dihydroxyapiol. Accordingly, a mass balance equation for apiol in
rat and human liver is as follows:
vALA=vt ¼ vUptakeA=vt þ QL ðCAA  CLA=PLAÞ
Vmax;HA  CLA

PLA

Km;HA þ CLA

PLA

Vmax;DHA  CLA

PLA

Km;DHA þ CLA

PLA

Vmax;ADD  CLA

PLA
ðKm; ADD þ CLA=PLAÞ
vUptake=vt ¼ vAGIA=vt ¼ Ka  AGIA;
AGIAð0Þ ¼ oral dose
CLA ¼ ALA=VL
Where uptakeA (mmol) is the amount of apiol taken up from the
gastrointestinal tract, AGIA (mmol) is the amount of apiol remaining
in the gastrointestinal tract, ALA (mmol) is the amount of apiol in
liver. CLA is the apiol concentration in the liver (mmol/L). CAA is the
apiol concentrations in the arterial blood (in mmol/L), QL is the
blood ﬂow rate to liver (L/h), VL is the volume of the liver (L), PLA is
the liver/blood partition coefﬁcient of apiol, and Vmax, and Km, are
the values representing the maximum rate of formation and
MichaeliseMenten constant, respectively, for the formation of 10-
hydroxyapiol (HA), 20,30-dihydroxyapiol (DHA), and 4-allyl-3,6-
dimethoxybenzene-1,2-diol (ADD).
In both models, the conversion of apiol to 20,30-dihydroxyapiol
and 4-allyl-3,6-dimethoxybenzene-1,2-diol are described, but
further reactions with these metabolites were not included in the
Fig. 3. Overview of the PBK model for apiol.
Table 1
Parameters used in the physiologically based biokinetic model for apiol in male rat.
Physiological parameters Tissue: blood partition coefﬁcients
Body wt (kg) 0.25
Percentage of body wt Apiol
Liver 3.4 Liver 2.40
Fat 7.0 Fat 75.93
Rapidly perfused 5.1 Rapidly perfused 2.40
Slowly perfused 60.2 Slowly perfused 0.80
Arterial blood 1.85
Venous blood 5.55
Cardiac output (L/h) 5.4
Percentage of cardiac output 10-hydroxyapiol
Liver 25.0 Liver 1.10
Fat 7.0
Rapidly perfused 51.0
Slowly perfused 17.0
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conjugates were completely excreted into the urine. Since the liver
is the major target organ for alkenylbenzene-induced carcinoge-
nicity in rats and mice, the present study focused primarily on
metabolic conversion of 10-hydroxyapiol by glucuronidation,
oxidation and sulfonation in the liver only. The mass balance
equation for 10-hydroxyapiol in rat and human liver is as follows:
RAT : vALHA=vt ¼ Vmax;HA  CLA

PLA

Km;HA þ CLA

PLA

Vmax;HAG  CLHA

PLHA

Km;HAG þ CLHA

PLHA

kHAO  CLHA=PLHA
kHAS  CLHA=PLHA
CLHA ¼ ALHA=VL
Human : vALHA=vt ¼ Vmax;HA  CLA

PLA

Km;HA þ CLA

PLA

Vmax;HAG  CLHA

PLHA

Km;HAG þ CLHA

PLHA

Vmax;HAO  CLHA

PLHA

Km;HAO þ CLHA

PLHA

kHAS  CLHA=PLHA
CLHA ¼ ALHA=VL
where ALHA is the amount of 10-hydroxyapiol in the liver (mmol),
CLHA is the 10-hydroxyapiol concentration in the liver (mmol/L), PLHA
is the liver/blood partition coefﬁcient of 10-hydroxyapiol, Vmax, and
Km, are the maximum rate of formation and MichaeliseMenten
constant, respectively, for the formation of the different apiol me-
tabolites, including 10-hydroxyapiol glucuronide (HAG) in the rat
and human liver and 10-oxoapiol (HAO) in human, and k is the ﬁrst
order rate constant for formation of 10-oxoapiol in rat, and 10-sul-
foxyapiol (HAS) in rat and human liver.
Vmax and Km values and ﬁrst order rate constants k in case of
absence of saturation (for oxidation in rat and sulfonation of 10-
hydroxyapiol) for the different metabolic pathways of apiol and 10-
hydroxyapiol were derived in vitro in the present study. Vmax values
that were derived in vitro expressed as nmol min1 (mg liver
microsomal or S9 protein)1 were scaled to values representing the
Vmax per mmol h1 (g liver)1 using microsomal yields of 35 mg/gliver in rat and 32 mg/g liver in human and S9 protein yields of
143 mg/g liver as deﬁned by Punt et al. (2008), (2009) based on
Medinsky et al. (1994) First order rate constants k expressed in
ml min1 (mg liver microsomal or S9 protein)1 were scaled to
values expressed in ml h1 per g liver using the same conversion
factor for microsomal and S9 protein yield.
Tables 1 and 2 summarize the physiological parameters (i.e.
tissue volumes, cardiac output and tissue blood ﬂows) for rat and
human respectively which were derived from literature (Brown
et al., 1997). Partition coefﬁcients were derived in silico based on
a method described by DeJongh et al. (1997) using the log Kow. Log
Kow values for apiol (ClogP 3.12) and 10-hydroxyapiol (ClogP 1.56)
were estimated using ChemBio3D 2010 (CambrigeSoft, USA). Mass
balance equations were coded and numerically integrated in Ber-
keley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA)
using the Rosenbrock0s algorithm for stiff systems. The PBK models
were run during 720 h after the dosing to allow full conversion of
the parent compound.
2.7. Model sensitivity analysis using normalized sensitivity
coefﬁcients
A sensitivity analysis was used to determine which parameters
have the greatest inﬂuence onmodel predictions, and performed as
described previously (Al-Subeihi et al., 2012,
2011bib_Al_Subeihi_et_al_2011; Martati et al., 2011a, 2012a, Punt
et al., 2008, 2009; van den Berg et al., 2012). For this purpose
normalized sensitivity coefﬁcients (SC) were determined using the
following equation: SC ¼ (C0 e C)/(P0 e P)$(P/C), with C being the
Table 2
Parameters used in the physiologically based biokinetic model for apiol in human.
Physiological parameters Tissue: blood partition coefﬁcients
Body wt (kg) 60
Percentage of body wt Apiol
Liver 2.6 liver 6.45
Fat 21.4 fat 104.74
Rapidly perfused 5.0 rapidly perfused 6.45
Slowly perfused 51.7 slowly perfused 4.08
Blood 7.9
Cardiac output (L/h) 310
Percentage of cardiac output 10-hydroxyapiol
Liver 22.7 Liver 1.55
Fat 5.2
Rapidly perfused 47.3
Slowly perfused 24.8
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output resulting from an increase in parameter value, P being the
initial parameter value and P0 representing the modiﬁed parameter
value. An increase of 5% in parameter values was used to analyse
the effect of a change in parameter on the formation of 10-
hydroxyapiol and 10-sulfoxyapiol (expressed as a percentage of the
dose over 720 h). Each parameter was analysed individually while
the other parameters were kept at their initial value.
2.8. Comparison of the newly developed apiol PBK models based
predictions with PBK model predictions for the structurally related
compound safrole
The PBK model-based predictions for the formation of 10-
hydroxyapiol and 10-sulfoxyapiol were compared to the PBK
model-based predictions for the dose-dependent formation of the
10-hydroxy and 10-sulfoxymetabolites of the structurally related
alkenylbenzene safrole. For this purpose the previously deﬁned
PBK models for safrole in rat and human described by Martati et al.
(2011a), (2012a) were used. For comparison with apiol, the models
describing the metabolism of safrole were also run for 720 h.
3. Results
To identify the organs involved in the metabolism of apiol in
both male rat and human, incubations were performed using
microsomal protein preparations from liver, kidney, lung and small
intestine. UPLC analysis of these incubations revealed that for both
rat and human conversion of apiol was detected only in incubations
with liver microsomes. An example of a chromatogram of an in-
cubation of apiol with male rat liver microsomes and NADPH as theFig. 4. Chromatogram showing the different metabolites of apcofactor was shown in Fig. 4.
Themetabolites formed in incubations with both rat and human
liver microsomes were 20,30-dihydroxyapiol (RT 1.5 min), 10-
hydroxyapiol (RT 2.4 min), and 4-allyl-3,6-dimethoxybenzene-1,2-
diol (RT 2.2 min). Identiﬁcation of 10-hydroxyapiol was done based
on comparison of the UV-spectrum and retention time of the
formed 10-hydroxyapiol with those of the speciﬁc synthesized
reference compound. Tentative identiﬁcation of 4-allyl-3,6-
dimethoxybenzene-1,2-diol, resulting from the O-demethylena-
tion of apiol (Benedetti et al., 1977; Beyer et al., 2006; Lee et al.,
1998), and 20,30-dihydroxyapiol was based on analogy to UPLC
chromatograms of metabolic conversions of safrole and the fact
that apiol-20,30-oxide, formed following incubation of apiol with
liver microsomes and NADPH, would be hydrolysed by epoxide
hydrolase to 20,30-dihydroxyapiol as was previously demonstrated
for the structurally related alkenylbenzenes (Al-Subeihi et al., 2011;
Martati et al., 2011a; Punt et al., 2008; Luo et al., 1992; Luo and
Guenthner, 1996; Guenthner and Luo, 2001). Beside the analogy
to UPLC chromatograph, the three metabolites formed are in line
with the overview of JECFA of the three primary biotransformation
pathways for methylenedioxy-substituted alkenylbenzenes
including safrole, myristicin and apiol (WHO, 2009). Safrole, myr-
isticin and apiol were reported to be converted primarily by 1,2
ring-O-demethenylation yielding diphenolic derivatives (Benedetti
et al., 1977; Beyer et al., 2006; Lee et al., 1998), by epoxidation of the
double bond in the allyl side-chain yielding 20,30-epoxide product
(Luo et al., 1992; Luo and Guenthner, 1996), and by hydroxylation of
the alkene side-chain to yield the 10-hydroxy metabolite (Miller
et al., 1983; Benedetti et al., 1977; Zangouras et al., 1981). Apiol
concentration-dependent formation of the various microsomal
metabolites was also characterised and the kinetic constants
derived from these data on the concentration-dependent micro-
somal metabolite formation of apiol in incubations with both male
rat and human liver samples are presented in Table 3.3.1. Glucuronidation of 10-hydroxyapiol to 10-hydroxyapiol
glucuronide by rat and human liver S9
UPLC analysis of incubations with male rat liver S9 or mixed
gender pooled human liver S9, UDPGA as cofactor and 10-hydrox-
yapiol as substrate revealed a peak at 1.5 min, representing 10-
hydroxyapiol glucuronide since this peak was increased with
increasing apiol concentration. Chromatographic analysis of blank
incubations performed in the absence of the cofactor UDPGA did
not show this peak at a retention time of 1.50 min, and the for-
mation and elution behaviour of themetabolitewas in analogous to
results from similar incubations with safrole (Martati et al., 2011b,iol formed in incubations with male rat liver microsomes.
Table 3
Kinetic constants for metabolism of apiol and 10-hydroxyapiol in incubations with SpragueeDawleymale rat liver microsomes or S9 fractions andmixed gender pooled human
liver microsomes or S9 fractions (n ¼ 3).
Species Rat Human
Metabolite Abbreviation Kma,b ± SD Vmaxa,c ± SD kd ± SD In vitro
catalytic
efﬁciencye
Kma,b ± SD Vmaxa,c ± SD kd ± SD In vitro
catalytic
efﬁciencye
Conversion of apiol Conversion of apiol
20 ,30-dihydroxyapiol DHA 152 ± 18 0.15 ± 0.01 0.99 67 ± 7 0.032 ± 0.026 0.48
10-hydroxyapiol HA 95 ± 19 0.10 ± 0.02 1.05 102 ± 38 0.035 ± 0.033 0.34
4-allyl-3,6-
dimethoxybenzene-
1,2-diol
ADD 37 ± 7.7 0.81 ± 0.07 21.89 137 ± 18 0.58 ± 0.45 4.2
Conversion of 10-hydroxyapiol Conversion of 10-hydroxyapiol
10-hydroxyapiol
glucuronide
HAG 621 ± 459 5.1 ± 1.8 8.21 381 ± 350 0.28 ± 0.19 0.74
10-oxoapiol HAO 13  105 ± 3  105 2592 ± 755.7 1.13 ± 0.28 0.44
10-sulfoxyapiol HAS 61  107 ± 15  107 45  107 ± 4  107
a Mean values of three independent measurements ± SD.
b mM.
c nmol min1 (mg microsomal or S9 protein)1.
d First order rate constant for product formation (ml/min/mg protein).
e ml min1 (mg microsomal or S9 protein)1, (Vmax/Km  1000 ml/ml).
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The 10-hydroxyapiol concentration-dependent increase in glu-
curonidation of 10-hydroxyapiol to 10-hydroxyapiol glucuronide in
incubations with both male rat and human liver fractions is pre-
sented in Fig. 5A and D respectively. The kinetic constants derived
from these data are presented in Table 3.
3.2. Oxidation of 10-hydroxyapiol to 10-oxoapiol by rat and human
liver microsomes
UPLC analysis of incubations with male rat liver microsomes or
mixed gender pooled human liver microsomes, NADþ as cofactor
and 10-hydroxyapiol as substrate revealed a peak at 2.0 min. In this
incubation GSH was also added to trap the reactive oxidation
metabolite 10-oxoapiol. The peak at 2.0 min was identiﬁed as the
GSH conjugate of 10-oxoapiol, GS-10-oxoapiol. Identiﬁcation of GS-
10-oxoapiol was done based on comparison of the UV-spectrum and
retention time of the formed GS-10-oxoapiol with those of the
synthesized reference compound.
The rate of oxidation of 10-hydroxyapiol in male rat liver mi-
crosomes and pooled human liver microsomes with increasing
concentrations of 10-hydroxyapiol is presented in Fig. 5B and E
respectively. Table 3 presents the kinetic constants derived from
these data.
3.3. Sulfonation of 10-hydroxyapiol to 10-sulfoxyapiol by rat and
human liver S9
The reactive 10-sulfoxyapiol formed upon sulfonation of the
proximate carcinogenic metabolite 10-hydroxyapiol was trapped by
using GSH. The scavengingmay be either chemically or catalysed by
the glutathione S-transferases present in the S9 incubations in
which the sulfonation of 10-hydroxyapiol was measured.
UPLC analysis of incubations with male rat liver S9 or mixed
gender pooled human liver S9, 10-hydroxyapiol, PAPS and GSH
revealed a peak at 1.3 min. The LC-MS analysis showed increased
signal of m/z 526 with negative ion mode. The ion at m/z 526 cor-
responds to the theoretically expected [MH]- mass of a GSH
adduct of 10-sulfoxyapiol. Fig. 5C and F presents the 10-hydroxyapiol
concentration dependent rate of formation of 10-sulfoxyapiol in
incubations with male rat liver S9 or mixed gender pooled human
liver S9. The kinetic constants for the conversion of 10-hydroxyapiol
to 10-sulfoxyapiol in rat and human liver derived from these dataare presented in Table 3.
3.4. Comparison of the kinetic constants for conversion of apiol and
10-hydroxyapiol by male rat and mixed gender pooled human tissue
fractions
In order to allow a comparison between the kinetic constants for
metabolism of apiol and 10-hydroxyapiol by male rat and mixed
gender pooled human tissue fractions, Vmax values that were
derived in vitro expressed as nmol min1 (mg microsomal or S9
protein)1 were scaled to values representing the Vmax per
mmol h1 (g tissue)1 using microsomal and S9 protein yields as
described in literature (Medinsky et al., 1994) and previously used
by Punt et al. (2008), (2009), Al-Subeihi et al. (2012), (2011) and
Martati et al. (2011a), (2012a). The in vivo Vmax values derived
accordingly, were used to calculate a scaled catalytic efﬁciency
(scaled Vmax in vivo/Km) for the formation of apiol metabolites
(Table 4). These values revealed that the catalytic efﬁciency for
formation of the proximate carcinogenic metabolite of apiol, 10-
hydroxyapiol, is 3.3 times higher in male rat liver than in human
liver. The difference in the formation rate is mainly due to the 3-fold
difference in the maximum velocity (Vmax) for the conversion of
apiol to 10-hydroxyapiol (see Table 3).
The formation of 10-hydroxyapiol glucuronide was found to
represent the main metabolic reaction for detoxiﬁcation of 10-
hydroxyapiol in rat and human liver while in rat liver the catalytic
efﬁciency for this conjugationwas found to be 11.2-fold higher than
in human.
For 10-hydroxyapiol oxidation, the scaled k for rat liver was
found to be 3.1 times lower than the scaled in vivo catalytic efﬁ-
ciency for human liver. While for sulfonation the scaled k was 1.3-
fold higher in rat liver than in human liver.
Altogether, the results revealed that glucuronidation of 10-
hydroxyapiol, representing a detoxiﬁcation pathway, are the most
important pathway in rat and in human for conversion of 10-
hydroxyapiol, and bioactivation of 10-hydroxyapiol by sulfonation
was found to represent only a minor pathway in both rat and
human.
3.5. Evaluation of apiol PBK model performance
Since there are no available quantitative experimental data on
the excretion of the apiol metabolites formed after metabolism in
Fig. 5. Concentration-dependent rate of (A) glucuronidation of 10-hydroxyapiol in incubations with pooled male rat liver S9 or (D) pooled human mixed gender liver S9, (B)
oxidation of 10-hydroxyapiol in incubations with pooled male rat liver microsomes or (E) pooled human mixed gender liver S9, and (C) sulfonation of 10-hydroxyapiol in pooled male
rat liver S9 or (F) pooled human mixed gender liver S9. Data points represent mean values ± SD of three or four individual experiments.
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developed PBK models for apiol could not be evaluated against
in vivo data. Therefore the evaluation of the PBK models for apiol
was based on the evaluation of the similar PBK models for safrole
and the other alkenylbenzenes, for which more in vivo data
allowing evaluation of the models were available. The performance
of the rat PBKmodel developed for safrole was evaluated byMartati
et al. (2011a) where the predicted and observed levels of a variety of
safrole metabolites in plasma or the urine of rats were compared.
The predicted and observed safrole metabolite levels were found to
be similar (Martati et al., 2011a). Besides that, a comparison could
be made between the predictions of the developed human PBK
model for safrole (Martati et al., 2012a) and the known in vivo data
for human plasma concentrations or the urinary excretion of
selected safrole metabolites. Furthermore a comparison of the
predictions of the developed PBKmodels for other alkenylbenzenes
(estragole and methyleugenol) (Al-Subeihi et al., 2012, 2011; Puntet al., 2008, 2009) and the reported plasma and urine levels of
their metabolites could be done to support the validity of devel-
oped PBK models for the alkenylbenzenes, thus indirectly sup-
porting the validity of the apiol models. Based on the above
considerations showing the validity of developed PBK models for
all other alkenylbenzenes, it was concluded that it is a reasonable
assumption that these models also adequately describe the
metabolite levels formed in vivo in both rat and human after
ingestion of different oral doses of apiol.
3.6. Apiol PBK model predictions for rat and human
Fig. 6A shows the PBK model-based predictions for the dose-
dependent formation of the different microsomal metabolites of
apiol in rat liver. 4-Allyl-3,6-dimethoxybenzene-1,2-diol appears to
be themajor metabolite formed amounting to 91.5e85% of the dose
with the percentage somewhat decreasing with increasing dose.
Table 4
Scaled kinetic constants for metabolic conversion of apiol and 10-hydroxyapiol by male rat and human liver fractions.
Species Metabolite Kma (mM) Scaled Vmax in vivob (mmol/h/g
tissue)
In vivo catalytic efﬁciencyc (ml/h/
g tissue)
kd ± SD (ml/min/mg
protein)
Scaled ke (ml/h/g
tissue)
Rat 20 ,30-dihydroxyapiol 152 ± 18 0.32 2.07
10-hydroxyapiol 95 ± 19 0.21 2.21
4-allyl-3,6-dimethoxybenzene-
1,2-diol
37 ± 8 1.7 46.00
10-hydroxyapiol glucuronide 621 ± 459 43.76 70.75
10-oxoapiol 13  105 ± 3  105 0.27
10-sulfoxyapiol 61  107 ± 15  107 0.052
Human 20 ,30-dihydroxyapiol 67 ± 7 0.061 0.92
10-hydroxyapiol 102 ± 38 0.67 0.66
4-allyl-3,6-dimethoxybenzene-
1,2-diol
138 ± 18 1.11 8.13
10-hydroxyapiol glucuronide 381 ± 350 2.40 6.31
10-oxoapiol 2592 ± 755.7 2.17 0.85
10-sulfoxyapiol 45  107 ± 4  107 0.039
a Mean values of three independent measurements ± SD.
b Scaled Vmaxwere converted from in vitro Vmax based on microsomal protein yield of 35 mg/g liver in rat and 32 mg/g liver in human and S9 protein yield of 143 mg/g liver.
c Catalytic efﬁciency (scaled Vmax(app)/Km).
d First order rate constant for product formation.
e Scaled k were converted from k based on microsomal protein yield of 35 mg/g liver and S9 protein yield of 143 mg/g liver.
Fig. 6. PBK-predicted dose-dependent changes in overall formation of (A) microsomal metabolites of apiol in rat liver and (B) metabolites of 10-hydoxyapiol in rat liver. The lines
correspond to (A) 4-allyl-3,6-dimethoxybenzene-1,2-diol (CCCC), 10-hydroxyapiol (━━━), and 20 ,30-dihydroxyapiol (▬ ▬), and (B) 10-hydroxyapiol glucuronide (▬ ▬), 10-sulfox-
yapiol (━━━), and 10-oxoapiol (CCCC).
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dicted to increase in a dose-dependent manner from 4% to about 7%
of the dose at low and high dose levels respectively. Concurrent
with the increase in the percentage of the dose that undergoes 10-
hydroxylation of the alkene side chain, a dose-dependent increase
from about 4% to 8% of the dose converted by epoxidation was
observed. Fig. 6B shows the PBK model-based predictions for the
dose-dependent increase in the formation of the metabolites of 10-
hydroxyapiol in rat liver. The percentage of the dose of apiol con-
verted to 10-sulfoxyapiol varies with the dose amounting to
0.0032% at a low dose of 0.05 mg/kg bw to 0.0050% of the dose at a
relatively high dose of 300 mg/kg bw, while these percentages
amounted to 0.017% at low dose to 0.026% at high dose for 10-
oxoapiol. Glucuronidation appears to be the major metabolic route
for 10-hydroxyapiol at all dose levels as 10-hydroxyapiol glucuro-
nide amounted to about 4.38% of the dose at low dose levels and to
6.80% of the dose at high dose levels.
Fig. 7A shows the PBK model-based predictions for the dose-
dependent formation of the different microsomal metabolites of
apiol in human liver. In human liver 4-allyl-3,6-
dimethoxybenzene-1,2-diol was predicted to be the major micro-
somal metabolite amounting to about 82.6e83.5% of the dose. In
human liver the percentage of the dose converted to 10-hydrox-
yapiol was only slightly decreased with the dose amounting to
6.7e6.3% of the dose. The decrease in the formation of 10-hydrox-
yapiol with increasing dose, is predicted to be accompanied by adecrease in the formation of apiol-20,30-oxide. Fig. 7B shows the
dose-dependent decrease in the relative formation of 10-hydrox-
yapiol glucuronide and 10-oxoapiol and the dose-dependent
decrease of the relative formation of 10-sulfoxyapiol in human
liver. There were only limited changes in the relative percentage of
the different metabolites with the dose. 10-Hydroxyapiol glucuro-
nide appears to be the major 10-hydroxyapiol metabolite amount-
ing to about 5.9e5.5% of the dose, while 10-oxoapiol amounts to
about 0.75% of the dose and 10sulfoxyapiol to 0.035% of the dose.
Fig. 8 shows a comparison of the relative extent of bioactivation
of apiol by rat and human liver. There are species differences in the
formation of 10-hydroxyapiol (Fig. 8A) and 10-sulfoxyapiol (Fig. 8B)
(expressed as nmol/g liver). In rat liver the formation of 10-
hydroxyapiol at low dose was almost 2 times lower than in human
liver and gradually increased with increasing the dose to reach
almost the same relative level as in human at high dose. Human
liver was predicted to be more efﬁcient in formation of 10-sulfox-
yapiol being 15-fold higher at low dose and 8-fold higher at high
dose than 10-sulfoxyapiol formation by rat liver (Fig. 8B). This
higher relative formation of 10-sulfoxyapiol in human than rat liver
in spite of the almost equal rate of formation of its metabolic pre-
cursor 10-hydroxyapiol in rat and human liver is due to the fact that
the glucuronidation of 10-hydroxyapiol in rat liver is around 10
times more efﬁcient than that in human liver providing increased
opportunity for the competing sulfonation. The difference in
overall formation of the 10-sulfoxyapiol formation between rat and
Fig. 7. PBK-predicted dose-dependent changes in overall formation of (A) microsomal metabolites of apiol in human liver and (B) metabolites of 10-hydoxyapiol in human liver. The
lines correspond to (A) 4-allyl-3,6-dimethoxybenzene-1,2diol (CCCC), 10-hydroxyapiol (━━━), and 20 ,30-dihydroxyapiol (▬ ▬), and (B) 10-hydroxyapiol glucuronide (▬ ▬), 10-
sulfoxyapiol (━━━), and 10-oxoapiol (CCCC).
Fig. 8. PBK-predicted dose-dependent formation of (A) 10-hydroxyapiol and (B) 10-sulfoxyapiol in rat and human liver.
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nation of the 10-hydroxyapiol since this difference appeared limited
with an only 1.35-fold higher ﬁrst order rate constant for sulfona-
tion in rat than human liver (see Table 3).
3.7. Sensitivity analysis
In order to know the model parameters that have the highest
impact on the formation of 10-hydroxyapiol and 10-sulfoxyapiol in
rat and human liver, a sensitivity analysis was performed. The
analysis was done at an apiol dose of 0.05 mg/kg body wt per day to
calculate the normalized sensitivity coefﬁcients for all model pa-
rameters. Normalized sensitivity coefﬁcient values higher than 0.1,
affecting the formation of 10-hydroxyapiol and 10-sulfoxyapiol in rat
and human liver, are shown in Fig. 9A and B. Fig. 9 shows that in
both rat and human the parameters that inﬂuence the formation of
both metabolites to the highest extent are the same. 10-Hydrox-
yapiol formation is mainly inﬂuenced by the kinetic constants for
formation of 10-hydroxyapiol (Vmax,HA, km,HA) and the kinetic con-
stants for formation of 4-allyl-3,6-dimethoxybenzene-1,2-diol
(Vmax,ADD, km,ADD). Besides the above parameters, 10-sulfoxyapiol
formation was inﬂuenced by kinetic constants for formation of 10-
hydroxyapiol glucuronide (Vmax,HAG, km,HAG) and of 10-sulfoxyapiol
(k,HAS).
3.8. Comparison of the PBK model-based prediction of bioactivation
of apiol by rat and human to the PBK model predictions for
bioactivation of the structurally related compound safrole
The PBKmodel-based predictions for bioactivation of apiol in rat
and human, were compared to the PBK model-based predictionsfor bioactivation of safrole to facilitate a read-across-based risk
assessment. Fig. 10 shows the dose-dependent formation of the 10-
hydroxy and 10-sulfoxy metabolites in rat liver as predicted by the
respective PBK models from dose levels representing estimated
human daily intakes up to dose levels causing liver tumors in ro-
dent bioassays with safrole. In rat liver the PBK model-based pre-
dicted formation of the proximate carcinogenic 10-hydroxy
metabolite was found to be 2.8-fold lower for apiol than for safrole
at low dose and 2.0-fold lower at the highest dose (Fig. 10A).
Fig. 10B shows the predicted model outcomes for the formation of
the ultimate carcinogenic 10sulfooxy metabolites of apiol and
safrole. In rat liver the formation of the 10-sulfoxymetabolite is
predicted to be about 3-fold lower for apiol than for safrole. For
both alkenylbenzenes the formation of their 10-sulfoxymetabolite
increases linearly with increase of the dose.
Fig. 11 shows the predicted dose-dependent formation of the 10-
hydroxymetabolites and 10-sulfoxymetabolites of apiol and safrole
in human liver. The predicted formation of the 10-hydroxy metab-
olite is predicted to be about 8-fold lower for apiol than for safrole
at low dose and about 6-fold lower at high dose levels. In human
liver the formation of the 10-sulfoxymetabolites of apiol is predicted
to be 2 times lower for apiol than for safrole.3.9. Implications for risk assessment
In order to evaluate the possible human health hazards due to
daily consumption of apiol, themargin of exposure (MOE) approach
can be used. The MOE is the preferred approach to assess the safety
of a compound that is carcinogenic and genotoxic (EFSA, 2005).
Carcinogenicity data for apiol from which a BMDL10 can be
derived are absent, hampering the application of theMOE approach
Fig. 9. Normalized sensitivity coefﬁcients for the formation of 10-hydroxy apiol (black) and 10-sulfoxyapiol (grey) in the liver of rat and human. S9PL ¼ S9 protein yield of the liver,
MPL ¼microsomal protein yield of the liver, Vmax the maximum velocity and Km the MichaeliseMenten constant for the formation of the different metabolites, k ¼ the kinetic rate
constant for a ﬁrst order reaction, ADD ¼ 4-allyl-3,6-dimethoxybenzene-1,2-diol, DHA, ¼ 20 ,30-di hydroxyapiol, HA ¼ 10-hydroxyapiol, HAG ¼ 10-hydroxyapiol glucuronide,
HAO ¼ 10-oxoapiol; HES ¼ 10-sulfoxyapiol.
Fig. 10. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 10-hydroxymetabolites and (B) 10-sulfoxymetabolites of apiol (━━━) and safrole (▬ ▬) in male rat liver.
Fig. 11. PBK-predicted dose-dependent formation (nmol/g liver) of (A) 10-hydroxymetabolites and (B) 10-sulfoxymetabolites of apiol (━━━) and safrole (▬ ▬) in human liver.
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PBK model predictions presented above indicate that at dose levels
in the range at which safrole exposed rodents develop tumors
(10e100 mg/kg body wt per day) (Long et al., 1963), the formation
of 10-sulfoxymetabolites of apiol in rat liver is about 3-fold lower
than that of safrole. Based on this result it can be assumed that the
PBK modelling supports use of the BMDL10 for tumor formation by
safrole for risk assessment of the related compound apiol making a
correction for the expected 3-fold lower formation of the ultimate
carcinogenic 10-sulfoxymetabolite assuming the same mode of ac-
tion for these two analogues. Depending on the differences of for-
mation of ultimate carcinogen of apiol and safrole in rat liver at
dose levels that induce liver tumor formation in rodents exposed to
safrole, the BMDL10 of safrole which amounts to 1.9e5.1 mg/kg
body wt per day (van den Berg et al., 2011) was multiplied by factor
of 3 resulting in a BMDL10 of 5.7e15.3 mg/kg body wt per day. The
estimated mean daily intake of apiol from spice and spice oil in the
USA was reported to amount to 4  105 mg/kg body wt per day
(WHO, 2009). Using a BMDL10 of 5.7e15.3 mg/kg body wt per day
and an estimated daily intake of apiol of 4  105 mg/kg body wt
per day the MOE for apiol would amount to 140,000e385,000. This
indicates that there would be a low concern and a low priority for
risk management of the current levels of exposure to apiol. For
comparison the MOE values of safrole can be given, obtained at the
estimated daily intake of safrole from spice and spice oil in USA that
amounts to 1  103 mg/kg body wt per day (WHO, 2009), and
using a BMDL10 of safrole of 1.9e5.1 mg/kg body wt per day. These
data result in an MOE for safrole of 1900e5100 indicating a priority
for risk management that is higher than for apiol.
4. Discussion
The present paper describes the deﬁnition of mode of action-
based PBK models for detoxiﬁcation and bioactivation of the alke-
nylbenzene apiol in rat and human and the use of predictions made
by these models to facilitate a read-across-based risk assessment to
the structurally related alkenylbenzene safrole (Martati et al.,
2011a, 2012a), for which in vivo carcinogenicity data are avail-
able. Previously, using a similar approach and read-across to
estragole and methyleugenol, the risks of exposure to elemicin for
which also no in vivo rodent tumor data were available could be
evaluated (van den Berg et al., 2012). The approach enables a pre-
liminary risk assessment of apiol for which in vivo toxicity data are
limited without the need for additional animal studies. The physi-
ological parameters for rat and human and the biochemical and
physiochemical parameters for apiol were deﬁned to develop the
apiol PBK models.
The newly developed PBK models for apiol provide insight into
the species-differences in the relative extent of bioactivation and
detoxiﬁcation, and could also be used to compare the level of
metabolic activation of apiol to that of safrole in male rat and hu-
man liver (Martati et al., 2011a, 2012a). Comparing the apiol and
safrole model-based predictions showed that the formation of the
proximate and ultimate carcinogenic metabolites of the two alke-
nylbenzenes in rat is predicted to be comparable within an order of
magnitude. The PBK models predict the formation of the ultimate
carcinogenic 10-sulfoxymetabolite at a dose level of 100 mg/kg
body wt, at which safrole is causing liver tumors in rodent animal
(WHO, 2009; Long et al., 1963), to be 3-fold lower for apiol than for
safrole in rat liver. In line with these differences, Randerath et al.
(1984), using 32P-postlabeling reported that the number of DNA
adducts formed by apiol in adult mouse liver was lower than for
safrole. In a parallel study, Phillips et al. (1984) reported that in
preweaning male mice the level of DNA adducts formed after
neonatal apiol exposure was about 12-fold lower than afterneonatal safrole exposure (Phillips et al., 1984). In addition, the
ability of apiol to form DNA adducts in cultured human (HepG2)
cells was reported to be 3e5 times lower than that of safrole (Zhou
et al., 2007).
It is important to note that the PBK model-based predictions
quantify the amount of the ultimate carcinogenic metabolite
formed and not the ability of these compounds to bind to DNA or
other macromolecules. One could argue that this reactivity may
differ between the different alkenylbenzene compounds and that
an increasing number of methoxy groups may reduce the electro-
philicity of the 10-sulfoxymetabolite or its carbocation decreasing
its ability to bind to DNA (Miller et al., 1983; Randerath et al., 1984).
However, given that the PBKmodel-based predicted differences are
in line with the currently available data from in vivo and cellular
in vitro studies on DNA adduct formation by apiol and safrole it is
concluded that these possible differences in electrophilicity of the
two 10-sulfoxymetabolites does not affect the predictions to an
extent that it would modify the conclusions of the current MOE
based preliminary risk assessment.
Based on the rat PBK model predictions for formation of the
related 10-sulfoxymetabolite, being 3-fold lower for apiol than for
safrole at dose levels that are known to induce tumors in safrole-
exposed rodent models, it was concluded that the BMDL10 that
would be expected in a rodent animal bioassay for apiol could be 3-
fold higher than that of safrole. Based on these considerations a
preliminary risk assessment was performed for apiol using the
MOE approach and an estimated BMDL10 for apiol, of 3 times the
BMDL10 for safrole (1.9e5.1 mg/kg body wt per day) (van den Berg
et al., 2011) and the MOE for apiol was calculated to amount to
140,000e385,000. It is of interest to note that the PBK model of the
present study predicted that the formation of the ultimate carci-
nogenic 10-sulfoxymetabolite of apiol in human liver would be
about 10 times higher than its formation in rat liver. This difference
is included in the MOE of 10 000 which was deﬁned to include a
factor of 10 for interspecies differences (EFSA, 2005). Given that the
MOE values actually obtained for apiol are 14e38-fold higher than
10 000 they could accommodate an even larger species difference
than the 10-fold difference now included in the MOE of 10,000
without leading to a different conclusion. Furthermore, comparison
of the MOE values obtained in the present study for apiol and
safrole, indicate a priority for risk management of safrole that is
higher than for apiol, due to its 3 times lower BMDL10 and its 25-
fold higher estimated daily intake.
In conclusion, the present study reports the development of
apiol PBK models for rat and human providing insight into the
occurrence of species differences in the metabolic activation of this
food-borne compound that is genotoxic and carcinogenic. In
addition the PBK model predictions were applied to support read-
across from safrole for which tumor data are available facilitating a
preliminary risk assessment for apiol for which limited in vivo data
are available. This example illustrates how PBK modelling can be
used to contribute to risk assessment eliminating the need for
animal bioassays thereby contributing to the 3Rs of animal testing
in human safety assessments.
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